NEW YORK — Cytena said on Tuesday that it has signed a two-year agreement to supply single-cell isolators to Applitech Pharmaceutical Equipment Technology for distribution in China.
Under the terms of the deal, Cytena will receive about $10 million in exchange for providing Guangzhou-based Applitech with nearly 100 of the devices, which include its Up Sight instrument, with the potential for additional sales in the future.
“Cytena's single-cell isolators have helped researchers across the world advance cell line development research," Jonas Schöndube, business area director for biosciences at Cytena parent firm Bico, said in a statement. "We're thrilled to expand our footprint in China and help drive innovation across gene therapies, biosimilars, and monoclonal antibodies."
Freiburg, Germany-based Cytena was acquired in 2019 by Cellink, which rebranded as Bico earlier this year.